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Background: There is evidence to support the use of highly cross-linked polyethylene (HXLPE) in patients undergoing
total hip arthroplasty. However, the beneﬁts for those undergoing total knee arthroplasty are uncertain, with conﬂicting
reports based on previous cohort analyses. The purpose of the present study was to compare the revision rates following
primary total knee arthroplasty with use of HXLPE as compared with conventional polyethylene (CPE) using data from the
National Joint Registry (NJR) for England, Wales and Northern Ireland.
Methods: We performed a retrospective analysis of primary total knee arthroplasties recorded in the NJR from
2003 to 2014. Cobalt-chromium (CoCr)-CPE and CoCr-HXLPE bearing surfaces were compared using all-cause
revision, aseptic revision, and septic revision as end points. Survival analyses were conducted using rates per 100
years observed, Kaplan-Meier survival estimates, and Cox regression hazard ratios (HRs) adjusted for age, sex,
American Society of Anesthesiologists (ASA) classiﬁcation, body mass index (BMI), lead surgeon grade, and
implant constraint. Secondary analyses compared the most commonly used HXLPEs (Zimmer Prolong, DePuy XLK,
and Stryker X3) against CPE for the 3 most common total knee arthroplasty systems (NexGen, PFC Sigma, and
Triathlon).
Results: In the present study of 550,658 total knee arthroplasties, the unadjusted aseptic revision rates were signiﬁ-
cantly lower following procedures performed with CPE (n = 513,744) as compared with those performed with HXLPE total
knee replacements (n = 36,914) (0.29 [95% conﬁdence interval (CI), 0.28 to 0.30] compared to 0.38 [95% CI, 0.35 to
0.42], p < 0.01). The 10-year HR associated with CPE was 0.4 (95% CI, 0.1 to 0.8, p = 0.03). There were no signiﬁcant
differences between the adjusted revision rates of HXPLE compared with CPE in individual analyses of the most common
total knee arthroplasty systems. However, for the subset of patients who were both <60 years of age and had a BMI of >35
kg/m2, the “second-generation” Stryker X3 HXLPE demonstrated signiﬁcantly better survival than its respective CPE, with
CPE having an HR of 2.6 (95% CI, 1.2 to 5.9) (p = 0.02).
Conclusions: Alternative bearings are marketed as having improved wear properties over traditional CoCr-CPE. This
registry-based analysis demonstrated no overall survival beneﬁt of HXLPE after a maximum duration of follow-up of 12
continued
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years. Because of their increased cost, the routine use of HXLPE bearings may not be justiﬁed. However, they may have a
role in speciﬁc “higher demand” groups such as patients <60 years of age and/or those with a BMI of >35 kg/m2.
Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete list of levels of evidence.
T
he demand for total knee arthroplasty is increasing and
is predicted to rise further over the next decade1. The
most common indication for revision is aseptic loos-
ening associated with polyethylene wear and osteolysis2. With
growing demand and heightened patient expectations, it is
essential to investigate and aid strategies that maximize
implant longevity and address modiﬁable factors associated
with implant failure.
Highly cross-linked polyethylene (HXLPE) was intro-
duced in the late 1990s with the intention of reducing wear and
debris-induced osteolysis following joint arthroplasty3. HXLPE
is developed by exposing ultra-high molecular weight poly-
ethylene (UHMWPE) to gamma radiation3. Radiation breaks
up intramolecular bonds and produces free radicals that pro-
mote cross-linking across multiple polymer chains, increasing
overall density and improving wear characteristics. Excess free
radicals produced during this process cause oxidative insta-
bility; therefore, in order to preserve mechanical properties,
further thermal treatments are required to help eliminate
them4. The inferred improvement in wear properties has been
demonstrated in vitro, prompting the introduction of HXLPE
for total hip arthroplasty in the 1990s5-8. HXLPE has been
clinically shown to have improved survival in comparison with
conventional UHMWPE polyethylene (CPE) and has started to
become the preferred choice for patients undergoing total hip
arthroplasty9-12.
The introduction of HXLPE for total knee arthroplasty
has been much more gradual because of the concerns about
reduced ductility and fatigue resistance3,13,14. In contrast to
the congruent “ball and socket” hip joint, the mechanics of
the knee include rolling, sliding, and rotational motion that
potentially put the polyethylene insert at greater risk of wear
by delamination, pitting, and fatigue failure15. In an attempt
to address these demands and improve wear behavior, dif-
ferent manufacturers have used their own unique methods of
annealing and remelting when processing HXLPEs3. “Second-
generation” HXLPEs were introduced in 2005 in an attempt to
reduce free radicals further by means of sequential irradiation
and annealing (X3 [Stryker]) or antioxidant stabilization (AOX
[DePuy], E1 [Biomet], Vivacit-E [Zimmer])3. Knee replace-
ment data from the Australian Orthopaedic Association
National Joint Registry suggest an overall survival beneﬁt of
HXLPE when compared with CPE with follow-up beyond 10
years16. However, there is still no consensus15 about the use of
HXLPE in total knee arthroplasty, and there is little evidence
about the performance of different types of HXLPE used in
individual total knee arthroplasty systems.
The purposes of this National Joint Registry (NJR) study
were (1) to establish the usage of HXLPE in England, Wales,
and Northern Ireland; (2) to provide further information
about the rates of revision for total knee arthroplasties per-
formed with use of HXLPE versus CPE; and (3) to present
evidence pertaining to the differential performance of HXLPE
and CPE within the most frequently used total knee arthro-
plasty systems.
Materials and Methods
Design
In this retrospective cohort study, data from the NJR forEngland, Wales and Northern Ireland were used to compare
the rates of revision (including all-cause revision, septic revi-
sion, and aseptic revision) of CoCr implants on CPE bearings
against those of CoCr implants on HXLPE bearings in patients
undergoing primary total knee arthroplasty.
Data
NJR data were used to analyze patients who had had a total
knee arthroplasty recorded within the NJR data set between
2003 and 2014. Overall, 669,411 total knee arthroplasties were
recorded in the NJR during this period. From this cohort,
118,753 patients were excluded because either the bearing
type could not be ascertained or it was not a CoCr-on-CPE or
CoCr-on-HXLPE bearing (Fig. 1). Of the remaining 550,658
total knee arthroplasties, 513,744 involved a CoCr-on-CPE
bearing and 36,914 involved a CoCr-on-HXLPE bearing.
Fig. 1
Flowchart of inclusion and exclusion criteria. TKA= total knee arthroplasty,
ZO = zirconium oxide, and TiN = titanium nitride.
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Age, sex, American Society of Anesthesiologists (ASA)
physical status classiﬁcation, body mass index (BMI), lead
surgeon grade, and implant constraint were recorded for each
patient. Implant manufacturer, brand, component details, and
catalog numbers were used to establish bearing type and the
use of CPE or HXLPE. These data also were used to identify
the most frequently used total knee arthroplasty brands and
the relative usage of CPE and HXLPE bearings within these
implant systems (NexGen [Zimmer], PFC Sigma [DePuy], and
Triathlon [Stryker]).
The preliminary analysis focused on the unadjusted
overall rates of revision (all-cause) for total knee arthroplasties
performed with use of CPE compared with HXLPE inserts.
With use of the reported reason for revision within the NJR,
further subanalyses were undertaken for septic revision (revi-
sion for the treatment of infection) and aseptic revision
(revision for any other reason). The rate of septic revision was
not expected to demonstrate inferiority or superiority of
HXLPE as the meniscal insert material is unlikely to be a risk
factor for infection; therefore, subsequent analyses focused on
aseptic revision.
To account for different total knee replacement designs
and the evolution of implants, further analysis included a
within-brand examination of CPE versus HXPLE for the 3
most common knee implants recorded within the NJR as
listed above. Additional subgroup analyses were conducted
Fig. 3
Line graph showing HXLPE usage in the NJR between 2003 and 2014.
Fig. 2
Line graph showing alternative bearing usage in the NJR between 2003 and 2014. ZO = zirconium oxide, and TiN = titanium nitride.
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on patients <60 years of age at time of primary total knee
arthroplasty and those with a BMI of >35 kg/m2 as these
factors were consistent predictors of the risk of aseptic
revision.
Statistical Analysis
Survival analyses were conducted with use of revision rates per
100 component-years observed, and 95% conﬁdence intervals
(CIs) were estimated using Poisson distributions. Secondary
TABLE I Revision Rates per 100 Component-Years
Component-
Years
All-Cause Revision Aseptic Revision Septic Revision
No. of
Revisions
No. of Revisions per
100 Component
Years*
No. of
Revisions
No. of Revisions per
100 Component
Years* No. of Revisions
No. of Revisions per
100 Component
Years*
CoCr-CPE (n = 513,744) 2,203,461 8,786 0.40 (0.39-0.41) 6,386 0.29 (0.28-0.30) 2,400 0.11 (0.10-0.11)
CoCr-HXLPE (n = 36,914) 141,726.6 698 0.49 (0.46-0.53) 542 0.38 (0.35-0.42) 156 0.11 (0.09-0.13)
CoCr-HXLPE without Kinemax
Duration (n = 27,418)
68,376.1 325 0.48 (0.43-0.53) 239 0.35 (0.31-0.40) 86 0.13 (0.10-0.16)
*The 95% CI is given in parentheses.
TABLE II Adjusted Cox Regression Estimates for CoCr-on-CPE Versus CoCr-on-HXLPE*
CPE (N = 513,744)† HXLPE (N = 36,914)†
Adjusted HRs with Aseptic
Revision as End Point‡
Female (ref., male) 295,916 (57.6%) 21,066 (57.1%) 1.0 (1.0-1.0)
ASA classiﬁcation
1 60,327 (11.7%) 4,640 (12.6%) Ref.
2 371,770 (72.4%) 26,387 (71.5%) 1.0 (1.0-1.1)
‡3 81,647 (15.9%) 5,887 (15.9%) 1.0 (0.9-1.1)
BMI
<30 kg/m2 127,305 (24.8%) 8,109 (22.0%) 1.0 (0.9-1.0)
30-35 kg/m2 89,146 (17.4%) 6,005 (16.3%) 1.0 (0.9-1.1)
>35 kg/m2 63,752 (12.4%) 4,724 (12.8%) 1.1# (1.1-1.2)
NA§ 233,541 (45.5%) 18,076 (49.0%) Ref.
Non-consultant as primary surgeon (ref.,
consultant as primary surgeon)
107,285 (20.9%) 7,391 (20.0%) 1.0 (0.9-1.1)
Posterior-stabilized (ref., cruciate-retaining) 157,761 (30.7%) 5,406 (14.6%) 1.2# (1.1-1.2)
Age
<60 yr 72,956 (14.2%) 6,898 (18.7%)
1-yr HR 1.8# (1.5-2.2)
3-yr HR 2.1# (1.7-2.7)
5-yr HR 2.5# (1.9-3.3)
10-yr HR 6.9 (0.9-53)
60-75 yr 280,895 (54.7%) 19,649 (53.2%)
1-yr HR 1.8# (1.5-2.2)
3-yr HR 1.9# (1.6-2.4)
5-yr HR 2.0# (1.6-2.7)
10-yr HR 4.6 (0.6-35)
>75 yr 159,893 (31.1%) 10,367 (28.1%) Ref.
CPE HR (ref., HXLPE)
1-yr HR - - 0.8 (0.6-1.0)
3-yr HR 0.8 (0.6-1.1)
5-yr HR 0.5# (0.4-0.7)
10-yr HR 0.4# (0.1-0.8)
*Ref. denotes reference group for multivariable analysis.†The values are given as the number of patients, with the percentage in parentheses.‡The 95% CI is given in
parentheses. §NA = not available. #P < 0.05.
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analyses compared the most commonly used HXLPEs (Pro-
long [Zimmer], XLK [DePuy], and X3 [Stryker]) within that
manufacturer’s speciﬁc total knee arthroplasty brand with use
of Kaplan-Meier survival estimates and Cox regression
hazard ratios (HRs); the predictors were age at the time of
the primary procedure (<60, 60 to 75, >75 years), sex (male,
TABLE III Subgroup Analysis of Most Commonly Used Total Knee Arthroplasty Brands: CoCr-on-CPE Versus CoCr-on-HXLPE*†
NexGen PFC Sigma Triathlon
CPE
(N = 71,429)
Prolong
First-Generation
HXLPE‡
(N = 1,657)
Adjusted
Aseptic
Revision HR§
CPE
(N = 161,160)
XLK
First-Generation
HXLPE#
(N = 5,773)
Adjusted
Aseptic
Revision HR§
CPE
(N = 31,448)
X3 Second-
Generation
HXLPE**
(N = 17,362)
Adjusted
Aseptic
Revision HR§
Female (ref., male) 41,679 (58.4%) 887 (53.5%) 0.9 (0.8-1.0) 92,295 (57.3%) 3,464 (60.0%) 1.0 (0.9-1.1) 18,293 (58.2%) 9,855 (56.8%) 1.2 (1.0-1.4)
Age
<60 yr 10,606 (14.8%) 277 (16.7%) 24,315 (15.1%) 1,365 (23.6%) 4,767 (15.2%) 3,458 (19.9%) 2.9†† (2.2-3.8)
1-yr HR 1.0 (0.5-1.8) 1.8†† (1.2-2.7)
5-yr HR 4.1†† (2.3-7.2) 2.8†† (1.9-3.9)
60-75 yr 39,301 (55.0%) 868 (52.4%) 88,747 (55.1%) 2,977 (51.6%) 16,873 (53.7%) 9,281 (53.5%) 1.5†† (1.1-1.9)
1-yr HR 0.9 (0.5-1.7) 1.8†† (1.2-2.7)
5-yr HR 2.0†† (1.2-3.4) 1.3 (1.0-1.8)
>75 yr 21,522 (30.1%) 512 (30.9%) Ref. 48,098 (29.8%) 1,431 (24.8%) Ref. 9,808 (31.2%) 4,623 (26.6%) Ref.
ASA classiﬁcation
1 7,239 (10.1%) 119 (7.2%) Ref. 16,887 (10.5%) 542 (9.4%) Ref. 3,070 (9.8%) 1,898 (10.9%) Ref.
2 52,444 (73.4%) 1,266 (76.4%) 1.0 (0.8-1.3) 117,422 (72.9%) 4,411 (76.4%) 1.1 (0.9-1.3) 23,075 (73.4%) 12,351 (71.1%) 1.0 (0.8-1.4)
‡3 11,746 (16.4%) 272 (16.4%) 0.9 (0.6-1.2) 26,851 (16.7%) 820 (14.2%) 1.1 (0.9-1.4) 5,303 (16.9%) 3,113 (17.9%) 1.1 (0.8-1.6)
BMI
<30 kg/m2 21,081 (29.5%) 388 (23.4%) 0.8 (0.7-1.0) 45,724 (28.4%) 1,455 (25.2%) 1.0 (0.9-1.2) 10,335 (32.9%) 4,653 (26.8%) 1.1 (0.9-1.5)
30-35 kg/m2 15,346 (21.5%) 298 (18.0%) 0.9 (0.7-1.1) 32,957 (20.4%) 1,158 (20.1%) 1.0 (0.9-1.2) 7,231 (23.0%) 3,500 (20.2%) 1.1 (0.8-1.4)
>35 kg/m2 11,157 (15.6%) 260 (15.7%) 1.1 (0.9-1.4) 24,546 (15.2%) 987 (17.1%) 1.2†† (1.0-1.3) 5,451 (17.3%) 2,695 (15.5%) 1.4†† (1.0-1.8)
NA§§ 23,845 (33.4%) 711 (42.9%) Ref. 57,933 (35.9%) 2,173 (37.6%) Ref. 8,431 (26.8%) 6,514 (37.5%) Ref.
Non-consultant as
primary surgeon
(ref., consultant as
primary surgeon)
16,932 (23.7%) 434 (26.2%) 1.0 (0.8-1.2) 30,110 (18.7%) 1,413 (24.5%) 1.0 (0.9-1.2) 7,283 (23.2%) 3,164 (18.2%) 1.0 (0.8-1.2)
Posterior-stabilized
(ref., cruciate-
retaining)
36,186 (50.7%) 374 (22.6%) 1.6†† (1.3-1.8) 49,752 (30.9%) 867 (15.0%) 1.1 (1.0-1.2) 7,797 (24.8%) 2,460 (14.2%) 1.0 (0.8-1.2)
*Ref. denotes reference group for multivariable analysis.†Unless otherwise speciﬁed (i.e., with the exception of the “AdjustedAsepticRevisionHR” columns), the valuesare givenas thenumber of
patients, with the percentage in parentheses.‡Irradiated at 65 kGy and remelted at 135C. §The 95% CI is given in parentheses. #Irradiated at 50 kGy, remelted at 155C and annealed at 120C.
**Irradiated at 90 kGy (3 · 30) and sequentially annealed at 130C. ††P < 0.05. §§Not available.
TABLE IV Revision Rates and Adjusted Cox Regression Estimates of Most Commonly Used Total Knee Arthroplasty Brands: CoCr-on-CPE
Versus CoCr-on-HXLPE*
NexGen PFC Sigma Triathlon
CPE (N = 71,429)
Prolong First-
Generation
HXLPE†
(N = 1,657) CPE (N = 161,160)
XLK First-
Generation
HXLPE‡
(N = 5,773) CPE (N = 31,448)
X3 Second-
Generation
HXLPE§
(N = 17,362)
No. of revisions per
100 component-years
All-cause revision 0.42 (0.40-0.45) 0.54 (0.31-0.87) 0.41 (0.39-0.42) 0.53 (0.40-0.69) 0.49 (0.45-0.54) 0.46 (0.40-0.53)
Aseptic revision 0.30 (0.28-0.32) 0.37 (0.18-0.66) 0.28 (0.27-0.30) 0.36 (0.26-0.50) 0.34 (0.30-0.38) 0.34 (0.28-0.40)
Septic revision 0.13 (0.11-0.14) 0.17 (0.05-0.39) 0.12 (0.11-0.13) 0.17 (0.10-0.27) 0.15 (0.13-0.18) 0.13 (0.09-0.16)
Adjusted CPE HR
All-cause revision 0.8 (0.5-1.2) [p = 0.3] 0.9 (0.7-1.2) [p = 0.5] 1.2 (1.0-1.4) [p = 0.1]
Aseptic revision 0.7 (0.4-1.3) [p = 0.3] 0.9 (0.7-1.3) [p = 0.7] 1.1 (0.9-1.3) [p = 0.5]
Septic revision 0.8 (0.3-2.0) [p = 0.6] 0.8 (0.5-1.4) [p = 0.6] 1.3 (0.9-1.8) [p = 0.1]
*The 95% CI is given in parentheses.†Irradiated at 65 kGy and remelted at 135C.‡Irradiated at 50 kGy, remelted at 155C, andannealed at 120C. §Irradiated at 90 kGy (3 ·30)
and sequentially annealed at 130C.
123
THE JOURNAL OF BONE & JOINT SURGERY d J B J S .ORG
VOLUME 102-A d NUMBER 2 d JANUARY 15, 2020
CONVENTIONAL VERSUS HIGHLY CROSS-LINKED POLYETHYLENE IN
PRIMARY TOTAL KNEE REPLACEMENT
female), ASA classiﬁcation (1, 2, 3, or 4), body mass index
(<30, 30 to 35, >35 kg/m2), lead surgeon grade (consultant
as primary surgeon, non-consultant as primary surgeon),
and constraint (cruciate-retaining, posterior-stabilized).
The assumption of proportionality was checked for each
model on the basis of Schoenfeld residuals. Any predictors
violating the proportional hazards assumption were reﬁtted
into the model as time-varying coefﬁcients. Time frame
split points were sequentially chosen until the Schoenfeld
global test was nonsigniﬁcant (p > 0.05). To control for
HXLPE availability and length of follow-up, the within-
brand secondary analyses were restricted to procedures
performed from 2008 to 2014. The present study was
exploratory in nature, using the complete data set of a
national registry; as such, no formal power calculation was
performed.
Analyses were performed with use of SPSS statistical
software (version 20.0; IBM) and STATA/IC (version 13.1;
StataCorp).
Results
The usage of HXLPE bearings during the period of obser-vation is shown in Figures 2 and 3.
Primary Analysis
Table I demonstrates that the unadjusted all-cause revision
rates (0.40 compared with 0.49 revision per 100 component-
years) and aseptic revision rates (0.29 compared with 0.38
revision per 100 component-years) were signiﬁcantly lower for
traditional CoCr-on-CPE total knee arthroplasties when
compared with the CoCr-on-HXLPE total knee arthroplasties
(p < 0.01 for both). This ﬁnding remained even after removing
Fig. 4 Fig. 5
Fig. 6 Fig. 7
Fig. 4 Unadjusted Kaplan-Meier survival curve for Zimmer NexGen with aseptic revision as the primary end point. CPE = blue line, and HXLPE = red line.
Fig. 5 Unadjusted Kaplan-Meier survival curve for DePuy PFC Sigma, with aseptic revision as the primary end point. CPE = blue line, and HXLPE = red
line.Fig. 6 UnadjustedKaplan-Meier survival curve for Stryker Triathlon, with aseptic revision as the primary end point. CPE=blue line, andHXLPE= red
line.Fig. 7 AdjustedCox regression survival curve for Stryker Triathlon in patients <60 years of age andwith a BMI of >35 kg/m2with aseptic revision as
the primary end point. CPE = blue line, HXLPE = red line, dashed lines = 95% CIs.
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9,496 Kinemax Plus total knee arthroplasties with the ﬁrst
annealed cross-linked Duration (unadjusted aseptic revision
rate, 0.35 per 100 component-years). Septic revision rates were
the same for the CPE and HXLPE groups (0.11 revisions per
100 component-years for both).
Table II demonstrates the results of the survival analysis
comparing CoCr-on-CPE versus CoCr-on-HXLPE with asep-
tic revision as the end point. CPE had a superior aseptic sur-
vival rate at 10 years (HR = 0.4 [95% CI, 0.1 to 0.8], p = 0.03).
Polyethylene Brand Analysis
The survival analyses of the 3 most commonly used HXLPE
brands (Zimmer Prolong, DePuy XLK, and Stryker X3) are
shown in Tables III and IV. There were no signiﬁcant differ-
ences in aseptic revision rates per 100 component-years for
CoCr-on-CPE and CoCr-on-HXLPE bearings for each of the 3
total knee arthroplasty systems. Figures 4, 5, and 6 show
unadjusted Kaplan-Meier survival curves comparing CPE with
its respective HXLPE for each total knee arthroplasty system.
No signiﬁcant difference was demonstrated between CPE and
HXLPE for any of these systems with use of the log-rank test
(Zimmer NexGen, p = 0.41; DePuy PFC Sigma, p = 0.27;
Stryker Triathlon, p = 0.98).
After adjustment for age, sex, BMI, ASA classiﬁcation,
lead surgeon grade, and constraint, Cox regression analysis
demonstrated no signiﬁcant differences in the rate of aseptic
revision between HXPLE and CPE for any of the 3 total knee
arthroplasty systems (Table IV). Sex, ASA classiﬁcation, and
lead surgeon grade were not signiﬁcant risk factors for aseptic
revision (p > 0.05 for all) (Table III).
Age, BMI, and Constraint Subgroup Analysis
Within the regression models, younger age (<60 years) and
high BMI (>35 kg/m2) were consistent predictors of the risk
of aseptic revision (Table III). Therefore, further analyses
were conducted on patients <60 years of age and/or with a
BMI of >35 kg/m2. Because of the limited numbers of HXLPE
cases available for analysis, the Zimmer Prolong HXLPE and
DePuy XLK HXLPE did not demonstrate a signiﬁcant dif-
ference in aseptic revision rates compared with their respec-
tive CPEs in unadjusted or adjusted analyses. However, for
patients <60 years of age, the Stryker X3 HXLPE had a sig-
niﬁcantly better survival rate than its respective CPE (HR =
1.5 [95% CI, 1.0 to 2.1]; p = 0.03). In addition, for patients
with a BMI of >35 kg/m2, the Stryker X3 HXLPE had a sig-
niﬁcantly better survival rate than its respective CPE (HR =
2.0 [95% CI, 1.2 to 3.3]; p < 0.01). For the subset of patients
who were both <60 years of age and had a BMI of >35 kg/m2,
the Stryker X3 HXLPE had a signiﬁcantly better survival rate
than its respective CPE (HR = 2.6 [95% CI, 1.2 to 5.9], p =
0.02) (Fig. 7).
Posterior cruciate-substituting total knee replacements
were a risk factor for aseptic revision in the Zimmer NexGen
subgroup (HR = 1.6 [95% CI, 1.3 to 1.8], p < 0.001). There
were signiﬁcantly fewer posterior cruciate-substituting total
knee replacements in the HXLPE group than in the CPE group
(22.6% compared with 50.7%, p < 0.001). Further analysis
restricted to posterior cruciate-substituting total knee re-
placements demonstrated no signiﬁcant difference in the rate
of aseptic revision with CPE compared with HXLPE (HR = 2.7
[95% CI, 0.4 to 20.0], p = 0.3). Posterior cruciate-substituting
total knee replacements were not identiﬁed as a signiﬁcant risk
factor for aseptic revision in the PFC Sigma or Stryker Tri-
athlon subgroups.
Discussion
HXLPEs are marketed as having improved wear propertiesover conventional polyethylene CPEs17-19 and have been
shown to reduce wear and improve implant survival in patients
undergoing total hip arthroplasty9-12. The present registry study
demonstrated that these beneﬁts are not generally translatable
to the total knee arthroplasty population in the intermediate
term. Overall, HXLPE demonstrated no survival beneﬁt after a
maximum duration of follow-up of 12 years. This preliminary
analysis compared CPE and HXLPE for all total knee replace-
ments in the NJR and as a result did not account for different
total knee replacement designs or the evolution of implants.
Therefore, individual brand analysis was conducted for the 3
most commonly used knee arthroplasty systems in England,
Wales, and Northern Ireland; this analysis demonstrated no
overall beneﬁt. However, further subgroup analysis suggested
that HXLPE may have a role in speciﬁc “higher-demand”
patient groups (patients with an age of <60 years and/or a BMI
of >35 kg/m2).
The limitations of the present study include the use of
revision within the registry as the end point, without consid-
eration of other potentially relevant outcomes such as patient-
reported outcomes, radiographic measures of wear, or retrieval
analysis of revised explanted implants. Missing information on
1 or both bearing surfaces occurred in 15.5% of the data set and
was excluded. We were unable to control for clinical or
departmental decision-making and possible selection bias for
the use ofHXLPE. The present study represents an intermediate-
term review of HXLPE performance, and greater follow-up is
needed in order to identify if HXLPE behavior changes over
longer-term follow-up.
The ﬁndings of the present study are consistent with data
from the Kaiser Permanente registry, with no difference in
revision rates between CPE and HXLPE20. While the overall
proportion of total knee arthroplasties with HXLPE in the
Kaiser Permanente registry is greater, the longer duration of
follow-up and the greater number of total knee arthroplasties
in the current study provide further insight into the behavior
of these implants.
The preliminary analysis included the Duration HXLPE
used with the Kinemax Plus total knee replacement. Duration
was the ﬁrst annealed cross-linked polyethylene and was
gamma-sterilized to 30 kGy and heated at 50C3. It has been
suggested that poor survival rates were seen with the Kinemax
Plus because of defective batches of polyethylene, with poor
wear characteristics and pitting noted in retrieval studies21. This
observation highlights the importance of differentiating
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between the different processes used by implant companies to
manufacture their HXLPEs. The ﬁrst HXLPEs were irradiated
at much lower doses and had less reﬁned thermal treatments;
remelting reduced mechanical and fatigue properties and an-
nealing was associated with higher free radical content. Con-
cerns about the ﬁrst HXLPE’s wear properties and risk of
fatigue cracking limited its use in knee replacement13,22. On
removing the ﬁrst HXLPE Duration from the analysis, there
was still no overall beneﬁt demonstratedwith the newerHXLPEs
over CPE.
The Stryker X3 HXLPE succeeded the Duration and
Crossﬁre HXLPEs, creating a “second-generation” HXLPE
with fewer free radicals, achieved by sequential irradiation
and an alternative annealing process3,23. Its time-zero
mechanical superiority and improved oxidative resistance
made it a more suitable and durable option for total knee
arthroplasty. This change occurred around the same time
that Stryker replaced the Kinemax total knee replacement
with the Triathlon total knee replacement24. Our results
demonstrated a superior survival rate in association with
the X3 HXLPE in patients aged <60 years and those with a
BMI of >35 kg/m2. Arguably, greater prosthesis loading in
younger patients (who are associated with a higher level of
activity) and heavier patients will cause CPE to wear faster25.
This ﬁnding is comparable with results from the Australian
Orthopaedic Association National Joint Replacement Reg-
istry (AOANJRR). de Steiger et al. demonstrated a reduced
failure rate for HXLPE in younger patients, which was
most pronounced for Zimmer NexGen Prolong total knee
arthroplasties16.
Prolong HXLPE, manufactured by Zimmer Biomet, is a
ﬁrst-generation HXLPE that is irradiated at a dose of 65 kGy
and remelted at 135C. We were unable to replicate the
AOANJRR’s ﬁndings with the Zimmer Prolong HXLPE in
the present study, possibly because there are substantially
fewer Prolong total knee arthroplasties in the NJR. Paxton
et al. found no signiﬁcant difference in survival in a study in
which 6,473 NexGen total knee replacements with Prolong
were compared with 25,320 NexGen total knee replace-
ments with CPE at 5 years26, similar to the current study.
The XLK HXLPE, manufactured by DePuy Synthes, is
another ﬁrst-generation HXLPE, which is irradiated at
50 kGy, remelted at 155C, and annealed at 120C. The
Kaiser Permanente Registry demonstrated no signiﬁcant
difference in survival when 2,291 PFC total knee arthro-
plasties with XLK were compared with 35,166 PFC total
knee arthroplasties with CPE26. The relatively small num-
bers of Prolong and XLK in our study are a further limita-
tion; these subgroup analyses should therefore be regarded
as exploratory.
Recent 10-year survival analyses, presented in the Aus-
tralian registry annual report, suggested a beneﬁt for HXLPE
over CPE following >100,000 total knee arthroplasties per-
formed with use of HXLPE inserts16. At 2.5 years of follow-up,
the hazard ratio for all-cause revision was 1.73 (95% CI, 1.60 to
1.86; p < 0.001). Currently, only 10% of total knee arthro-
plasties in England,Wales, and Northern Ireland are performed
with use of HXLPE inserts, compared with >50% in the Aus-
tralian registry. It is difﬁcult to reconcile the differing ﬁndings
between these 2 registries. The difference may relate to
“selective” use within the NJR, with HXLPE being reserved for
patients in whom excessive wear is predicted, such as the
younger, higher-demand patients, who are known to have a
higher rate of revision when compared with more elderly,
sedentary patients. While the current analysis adjusted for
patient-related factors, including age, we could not adjust for
patient function, preoperative expectation, disease severity, and
other factors that may confound comparison when 1 implant is
used “selectively.”
The use of HXLPEs as the bearing interface for total
knee arthroplasty is increasing in the NJR. The present study
suggests that there is no survival beneﬁt in association with
ﬁrst-generation HXLPEs (Duration, Prolong XLK) after a
maximum duration of follow-up of 12 years. As such, the
extra costs associated with these bearings may not be justiﬁed
in the intermediate term. Second-generation HXLPEs (X3)
may be beneﬁcial for patients who are young (<60 years) and/
or obese (BMI >35 kg/m2). Additional follow-up is required
to assess whether HXLPEs become a cost-effective alternative
to CPE in the longer term. n
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